Results 21 to 30 of about 5,013 (195)

A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation

Journal of Oncology Pharmacy Practice, 2023
Objective: The purpose of this study was to investigate the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of chemotherapy-induced nausea and vomiting (CINV) for hematopoietic cell transplantation (HCT) patients receiving BEAM ...
J. Bubalo, J. Radke, K. Bensch, A. Chen, S. Misra, R. Maziarz   +5 more
semanticscholar   +1 more source

Efficacy and safety analysis of dexamethasone + palonosetron in prevention of post-embolization syndrome after D-TACE: A retrospective study

Medicine, 2023
To investigate the efficacy and safety of dexamethasone + palonosetron in the prevention of post-embolization syndrome after drug-eluting beads transcatheter arterial chemoembolization (D-TACE).
Haohao Lu, Chuansheng Zheng, B. Liang, X. Xia   +3 more
semanticscholar   +1 more source

A comparison of prophylactic antiemetic therapy with palonosetron and dexamethasone as single-agents or in combination in adult patients undergoing laparoscopic surgery: A randomized trial

International Journal of Critical Illness and Injury Science, 2023
Background: The incidence of postoperative nausea and vomiting (PONV) is quite high after laparoscopic surgeries. This study endeavors to compare the efficacy of the combination of palonosetron and dexamethasone with that of either drug alone in the ...
Neha Sadhoo, J. Prakash, Vishwanath Kumar, R. Kharwar, Sabih Ahmad, Bijaya Kumar Sethi   +5 more
semanticscholar   +1 more source

Palonosetron, a 5-HT3 Receptor Antagonist, Induces G1 Cell Cycle Arrest and Autophagy in Gastric Cancer Cells. [PDF]

Int J Mol Sci
Serotonin or 5-hydroxytryptamine (5-HT) has been implicated in promoting cancer cell growth by acting on 5-HT receptors, such as 5-HT1 and 5-HT2 receptors. However, the role of 5-HT3 receptor antagonists in gastric cancer cell lines remains unclear. This
Yoo YC, Lin L, Lee S, Shin YR, Oh JE, Kim NY.   +5 more
europepmc   +2 more sources

Comparison of the ED50 of prophylactic butorphanol in preventing morphine-induced pruritus with or without palonosetron: a prospective, double-blinded, randomized dose–response trial using an up-down sequential allocation method

Annals medicus, 2023
Background Butorphanol has been used to reduce the incidence and severity of neuraxial morphine-induced pruritus. Palonosetron is a commonly used antiemetic for the prevention of postoperative nausea and vomiting.
Li-hong Sun, Lin Jin, C. Jiao, Luyang Wang, Qi Xu, Hui Wu, Xinzhong Chen   +6 more
semanticscholar   +1 more source

All Eyes on Me, Please: Ocular Palonosetron for the Cancer Patient with Nausea and Vomiting

Journal of Pharmacology and Experimental Therapeutics, 2023
The March issue of the Journal of Pharmacology and Experimental Therapeutics offers an interesting read on palonosetron for managing nausea and vomiting in beagle dogs treated with the anticancer agent cisplatin (Levijoki et al., 2023).
G. Minotti
semanticscholar   +1 more source

Comparative Study of Ondansetron and Palonosetron for Prevention of Nausea and Vomiting Following Upper Abdominal Surgeries under General Anaesthesia: A Randomised Control Trial [PDF]

Journal of Clinical and Diagnostic Research, 2020
Introduction: Postoperative Nausea and Vomiting (PONV) is a common entity following surgical procedure. It may result into serious complication like aspiration of gastric contents, prolonged recovery period.
Deepak Premnarayan Gupta, Vijay Chandak
doaj   +1 more source

Retrospective Evaluation of a Dexamethasone Sparing Antiemetic Regimen: An Antiemetic Prophylaxis Study on NEPA (Netupitant Plus Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients

Cureus, 2023
Background Corticosteroids, specifically dexamethasone (DEX), have been extensively utilized for the prevention of chemotherapy-induced nausea and vomiting (CINV). However, their usage is associated with a range of adverse events.
Suhas Agre, Madhura Agre, Pooja Pol, Mubarakunnisa Tonse, Mitasha Mohanty, Alfiya Shaikh   +5 more
semanticscholar   +1 more source

Pharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trial [PDF]

BMC Med
Zhao Y, Ma Y, Yin T, Qin Z, Liu L, Kong G, Zhang R, Huang Y, Zhang L, Zhao H.   +9 more
europepmc   +3 more sources

Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia [PDF]

Korean Journal of Anesthesiology, 2018
Background The aim of this study was to evaluate aprepitant in combination with palonosetron as compared to palonosetron alone for the prevention of postoperative nausea and vomiting (PONV) in female patients receiving fentanyl- based intravenous patient-
Jae Hwa Yoo, Soon Im Kim, Ji Won Chung, Mi Roung Jun, Yoo Mi Han, Yong Jik Kim   +5 more
doaj   +1 more source